224 related articles for article (PubMed ID: 19818690)
1. Effect of ascorbic acid in patients with Charcot-Marie-Tooth disease type 1A: a multicentre, randomised, double-blind, placebo-controlled trial.
Micallef J; Attarian S; Dubourg O; Gonnaud PM; Hogrel JY; Stojkovic T; Bernard R; Jouve E; Pitel S; Vacherot F; Remec JF; Jomir L; Azabou E; Al-Moussawi M; Lefebvre MN; Attolini L; Yaici S; Tanesse D; Fontes M; Pouget J; Blin O
Lancet Neurol; 2009 Dec; 8(12):1103-10. PubMed ID: 19818690
[TBL] [Abstract][Full Text] [Related]
2. Ascorbic acid for Charcot-Marie-Tooth disease type 1A in children: a randomised, double-blind, placebo-controlled, safety and efficacy trial.
Burns J; Ouvrier RA; Yiu EM; Joseph PD; Kornberg AJ; Fahey MC; Ryan MM
Lancet Neurol; 2009 Jun; 8(6):537-44. PubMed ID: 19427269
[TBL] [Abstract][Full Text] [Related]
3. Ascorbic acid in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial.
Pareyson D; Reilly MM; Schenone A; Fabrizi GM; Cavallaro T; Santoro L; Vita G; Quattrone A; Padua L; Gemignani F; Visioli F; Laurà M; Radice D; Calabrese D; Hughes RA; Solari A; ;
Lancet Neurol; 2011 Apr; 10(4):320-8. PubMed ID: 21393063
[TBL] [Abstract][Full Text] [Related]
4. Oral high dose ascorbic acid treatment for one year in young CMT1A patients: a randomised, double-blind, placebo-controlled phase II trial.
Verhamme C; de Haan RJ; Vermeulen M; Baas F; de Visser M; van Schaik IN
BMC Med; 2009 Nov; 7():70. PubMed ID: 19909499
[TBL] [Abstract][Full Text] [Related]
5. High-dosage ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A: results of a randomized, double-masked, controlled trial.
Lewis RA; McDermott MP; Herrmann DN; Hoke A; Clawson LL; Siskind C; Feely SM; Miller LJ; Barohn RJ; Smith P; Luebbe E; Wu X; Shy ME;
JAMA Neurol; 2013 Aug; 70(8):981-7. PubMed ID: 23797954
[TBL] [Abstract][Full Text] [Related]
6. Poor tolerability of high dose ascorbic acid in a population of genetically confirmed adult Charcot-Marie-Tooth 1A patients.
Toth C
Acta Neurol Scand; 2009 Aug; 120(2):134-8. PubMed ID: 19154534
[TBL] [Abstract][Full Text] [Related]
7. Selected items from the Charcot-Marie-Tooth (CMT) Neuropathy Score and secondary clinical outcome measures serve as sensitive clinical markers of disease severity in CMT1A patients.
Mannil M; Solari A; Leha A; Pelayo-Negro AL; Berciano J; Schlotter-Weigel B; Walter MC; Rautenstrauss B; Schnizer TJ; Schenone A; Seeman P; Kadian C; Schreiber O; Angarita NG; Fabrizi GM; Gemignani F; Padua L; Santoro L; Quattrone A; Vita G; Calabrese D; ; Young P; Laurà M; Haberlová J; Mazanec R; Paulus W; Beissbarth T; Shy ME; Reilly MM; Pareyson D; Sereda MW
Neuromuscul Disord; 2014 Nov; 24(11):1003-17. PubMed ID: 25085517
[TBL] [Abstract][Full Text] [Related]
8. Ascorbic acid for the treatment of Charcot-Marie-Tooth disease.
Gess B; Baets J; De Jonghe P; Reilly MM; Pareyson D; Young P
Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD011952. PubMed ID: 26662471
[TBL] [Abstract][Full Text] [Related]
9. An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A.
Attarian S; Vallat JM; Magy L; Funalot B; Gonnaud PM; Lacour A; Péréon Y; Dubourg O; Pouget J; Micallef J; Franques J; Lefebvre MN; Ghorab K; Al-Moussawi M; Tiffreau V; Preudhomme M; Magot A; Leclair-Visonneau L; Stojkovic T; Bossi L; Lehert P; Gilbert W; Bertrand V; Mandel J; Milet A; Hajj R; Boudiaf L; Scart-Grès C; Nabirotchkin S; Guedj M; Chumakov I; Cohen D
Orphanet J Rare Dis; 2014 Dec; 9():199. PubMed ID: 25519680
[TBL] [Abstract][Full Text] [Related]
10. A multicenter, randomized, double-blind, placebo-controlled trial of long-term ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL): the study protocol [EudraCT no.: 2006-000032-27].
Pareyson D; Schenone A; Fabrizi GM; Santoro L; Padua L; Quattrone A; Vita G; Gemignani F; Visioli F; Solari A;
Pharmacol Res; 2006 Dec; 54(6):436-41. PubMed ID: 17029975
[TBL] [Abstract][Full Text] [Related]
11. NT-3 promotes nerve regeneration and sensory improvement in CMT1A mouse models and in patients.
Sahenk Z; Nagaraja HN; McCracken BS; King WM; Freimer ML; Cedarbaum JM; Mendell JR
Neurology; 2005 Sep; 65(5):681-9. PubMed ID: 16157899
[TBL] [Abstract][Full Text] [Related]
12. A meta-analysis of randomized double-blind clinical trials in CMT1A to assess the change from baseline in CMTNS and ONLS scales after one year of treatment.
Mandel J; Bertrand V; Lehert P; Attarian S; Magy L; Micallef J; Chumakov I; Scart-Grès C; Guedj M; Cohen D
Orphanet J Rare Dis; 2015 Jun; 10():74. PubMed ID: 26070802
[TBL] [Abstract][Full Text] [Related]
13. [Ascorbic Acid and Charcot-Marie-Tooth Disease].
Noto Y
Brain Nerve; 2015 Oct; 67(10):1241-6. PubMed ID: 26450076
[TBL] [Abstract][Full Text] [Related]
14. A double-blind, placebo-controlled, randomized trial of PXT3003 for the treatment of Charcot-Marie-Tooth type 1A.
Attarian S; Young P; Brannagan TH; Adams D; Van Damme P; Thomas FP; Casanovas C; Kafaie J; Tard C; Walter MC; Péréon Y; Walk D; Stino A; de Visser M; Verhamme C; Amato A; Carter G; Magy L; Statland JM; Felice K
Orphanet J Rare Dis; 2021 Oct; 16(1):433. PubMed ID: 34656144
[TBL] [Abstract][Full Text] [Related]
15. Neuropathy progression in Charcot-Marie-Tooth disease type 1A.
Shy ME; Chen L; Swan ER; Taube R; Krajewski KM; Herrmann D; Lewis RA; McDermott MP
Neurology; 2008 Jan; 70(5):378-83. PubMed ID: 18227419
[TBL] [Abstract][Full Text] [Related]
16. Charcot-Marie-Tooth disease type 1A: is ascorbic acid effective?
Pareyson D; Solari A
Lancet Neurol; 2009 Dec; 8(12):1075-7. PubMed ID: 19818689
[No Abstract] [Full Text] [Related]
17. Treatment of Duchenne muscular dystrophy with ciclosporin A: a randomised, double-blind, placebo-controlled multicentre trial.
Kirschner J; Schessl J; Schara U; Reitter B; Stettner GM; Hobbiebrunken E; Wilichowski E; Bernert G; Weiss S; Stehling F; Wiegand G; Müller-Felber W; Thiele S; Grieben U; von der Hagen M; Lütschg J; Schmoor C; Ihorst G; Korinthenberg R
Lancet Neurol; 2010 Nov; 9(11):1053-9. PubMed ID: 20801085
[TBL] [Abstract][Full Text] [Related]
18. A Rasch Analysis of the Charcot-Marie-Tooth Neuropathy Score (CMTNS) in a Cohort of Charcot-Marie-Tooth Type 1A Patients.
Wang W; Guedj M; Bertrand V; Foucquier J; Jouve E; Commenges D; Proust-Lima C; Murphy NP; Blin O; Magy L; Cohen D; Attarian S
PLoS One; 2017; 12(1):e0169878. PubMed ID: 28095456
[TBL] [Abstract][Full Text] [Related]
19. Ascorbic acid for treatment of CMT1A: the jury is still out.
Shy M
Lancet Neurol; 2009 Jun; 8(6):505-7. PubMed ID: 19427270
[No Abstract] [Full Text] [Related]
20. Hand involvement in children with Charcot-Marie-Tooth disease type 1A.
Burns J; Bray P; Cross LA; North KN; Ryan MM; Ouvrier RA
Neuromuscul Disord; 2008 Dec; 18(12):970-3. PubMed ID: 18993073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
